Supervised Esketamine Treatment with Spravato® (Esketamine)
SPRAVATO® is a prescription nasal spray for adults with treatment-resistant depression and, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. It is administered under direct healthcare-provider supervision through the SPRAVATO® REMS program.
- Coverage varies by plan — confirm with your insurer
- Administered in healthcare settings under the REMS
At least 2 hours of post-dose observation
How Esketamine Differs From Traditional Antidepressants
Traditional oral antidepressants mainly act on monoamine systems such as serotonin and norepinephrine. Esketamine works through a different pathway: it is an NMDA receptor antagonist that affects glutamate signaling.
Early Symptom Changes in Studies
Oral antidepressants often take several weeks to reach full effect. Some SPRAVATO® clinical studies measured differences in depressive symptoms as early as 24 hours after the first dose. Individual response varies.
A Different Neurochemical Pathway
Rather than primarily targeting serotonin or norepinephrine reuptake, esketamine blocks NMDA receptors and influences glutamate signaling. Researchers are still studying how its downstream effects relate to its antidepressant action.
Studied in Treatment-Resistant Depression
SPRAVATO® is approved for adults with treatment-resistant depression, alone or with an oral antidepressant. In clinical trials, SPRAVATO® plus a new oral antidepressant reduced depressive symptoms more than placebo plus an oral antidepressant.
What to Expect: Administration & Observation Protocol
SPRAVATO® is administered only in healthcare settings under direct supervision, with monitoring after each dose to help manage potential risks.
Self-Administered Nasal Spray
Blood pressure is checked before dosing. You then self-administer the SPRAVATO® nasal spray under the direct supervision of a healthcare provider, following the labeled dosing instructions.
Supervised Observation Period
You remain at the treatment setting for at least two hours while the healthcare team monitors blood pressure, alertness, breathing, and effects such as sedation or dissociation. Blood pressure is rechecked at approximately 40 minutes after dosing.
Departure & Transportation
You may leave when the healthcare provider determines it is appropriate. Because SPRAVATO® can affect alertness and coordination, do not drive or operate machinery until the next day after a restful sleep.
Safety First: The FDA REMS Program Protection
SPRAVATO® is available only through a restricted program called the SPRAVATO® REMS (Risk Evaluation and Mitigation Strategy). It must be administered in a healthcare setting under direct supervision, with monitoring after each dose.
Supervised Healthcare Setting
SPRAVATO® is not taken home. Each dose is self-administered in a healthcare setting under direct supervision, followed by monitoring.
Controlled Access
Esketamine is a Schedule III controlled substance with potential for abuse and misuse. The REMS restricts distribution to help reduce these risks.
Sedation & Dissociation
Sedation, dizziness, and dissociation (changes in perception, awareness, or sense of time) can occur after dosing. The healthcare team monitors these effects before you leave.
Blood Pressure & Breathing
Blood pressure is assessed before dosing and approximately 40 minutes after. Respiratory status is monitored for at least two hours after each dose.
Preliminary Spravato® Screening
Answer three short questions about treatment history, treatment-day logistics, and oral antidepressant use. This is an informational tool — not a diagnosis or eligibility determination.
- Independent clinic directory
- Answers stay in your browser and are not submitted
*Informational tool only. It does not provide a diagnosis or determine eligibility. A qualified healthcare professional determines whether SPRAVATO® is appropriate.
Explore our curated selection of articles on Spravato® (Esketamine) Therapy

The Power of Collaboration: How Patients, Clinics & Manufacturers Shape TMS & Spravato Treatment
At MDDCare, we believe that TMS therapy and Spravato (Esketamine) can be life-changing—but their impact grows when patients, clinics, and manufacturers collaborate.…Read article
Cutting-Edge Treatments for MDD: What’s Changing in Depression Care
Depression treatment is advancing beyond traditional medications. If you’ve struggled with antidepressants or are looking for more effective options, you’ll be glad…Read article
Struggling with Depression? How TMS & Spravato Can Help When Medications Don’t
Tried multiple antidepressants with little to no relief? You’re not alone. Many people with treatment-resistant depression (TRD) feel stuck, but there’s hope…Read article
Why Psychiatrists may continue try antidepressant medications when there is a better option
Tried multiple antidepressants without success? You’re not alone. Many psychiatrists continue prescribing antidepressants—even when patients don’t see improvements—because it’s often the standard…Read article
Are You Born with Depression? How Genetics Influences MDD
Is depression something you’re born with, or does it develop over time? While life experiences and environment play a role, genetics can…Read article
Is Your Teen Depressed? Recognizing the Early Signs of MDD
Teenagers go through mood swings, but when does sadness turn into something more serious? Major Depressive Disorder (MDD) in teens can be…Read articleSpravato® Specific Frequently Asked Questions
Educational answers about esketamine treatment. Discuss your situation with a qualified healthcare professional.
How is esketamine different from ketamine?
Esketamine is one form (the S-enantiomer) of the ketamine molecule. SPRAVATO® is an FDA-approved esketamine nasal spray with specific indications, dosing, monitoring, and safety requirements. Ketamine products may be used in other clinical contexts that are not covered by the SPRAVATO® labeling.
Is Spravato® covered by insurance?
Coverage varies by insurance plan, clinical indication, treatment setting, and plan requirements, and many plans require prior authorization. Confirm benefits, authorization requirements, and expected costs directly with your insurer and the clinic. MDDCare does not determine coverage.
What does the treatment experience feel like?
Experiences vary. Common effects after dosing include dissociation (changes in perception, awareness, or sense of time), dizziness, sedation, nausea, and increased blood pressure. These effects are monitored by the healthcare team for at least two hours after each dose.
How often will I need to attend the clinic?
For treatment-resistant depression, the FDA-approved schedule is twice weekly in weeks 1–4 and once weekly in weeks 5–8. From week 9, treatment is once weekly or every two weeks, individualized to the least frequent dosing that maintains response. The treating healthcare professional determines the schedule.